Cardiovascular diabetology. Endocrinology reportsAug 30, 2026

Which types of heart failure may benefit from GLP-1 receptor agonists?

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Sep 1, 2026

Abstract

Evidence for GLP-1 receptor agonists in heart failure with reduced ejection fraction (HFrEF) is limited.

Pooled analyses suggest GLP-1 receptor agonists reduce heart failure hospitalization.
The applicability of this benefit across different heart failure phenotypes remains uncertain.
Trials focused on obesity-associated heart failure with preserved ejection fraction (HFpEF) involved highly selected populations.
Cardiovascular outcome trials did not provide detailed heart failure phenotyping.
Standardized heart failure phenotyping and specific analyses are needed to determine the potential benefits of GLP-1 receptor agonists across various heart failure types.

Simplified

GLP‑1 receptor agonists reduce heart failure hospitalization in pooled analyses, but whether this benefit applies across the spectrum of heart failure phenotypes remains unclear. This correspondence highlights that dedicated trials showing efficacy in obesity‑associated HFpEF enrolled highly selected populations, whereas the included cardiovascular outcome trials lacked detailed heart failure phenotyping. Evidence for GLP‑1RAs in HFrEF is limited. We call for standardized heart failure phenotyping and phenotype‑specific analyses to clarify whether the observed benefit is a class effect or preferentially confined to metabolically defined subgroups.

Full Text

Full text is available at the source.

View Full Text ↗

Which types of heart failure may benefit from GLP-1 receptor agonists?

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief